28 Dec, 2020
HyTest Group Welcomes Juhana Rauramo as its New CEO

Juhana Rauramo will become the new CEO of HyTest Group Oy with effect from January 1, 2021. Juhana has proven to be a very valuable person for HyTest and he has agreed to take on a more extensive role regarding the management of the company. Meanwhile, Maria Severina, the Founder and CEO of the company for the last 26 years will continue as a board member for HyTest Group Oy and she will be available as a consultant to the company.
Juhana has been the CCO of HyTest and a member of the management team since September 2019.

Read more
21 Dec, 2020
Season's Greetings 2020

In this exceptional year we must make exceptional actions. Check our Season's Greetings video to you:

Read more
10 Dec, 2020
Meet HyTest Team at Virtual AACC Expo

Connect with our representative during the AACC virtual expo, taking place December 14–17. Schedule a meeting at our booth through the virtual platform or contact us already now and agree a meeting.

Our new Sales Manager Outi Vilamo will be also waiting to meet you there.

Read more
08 Dec, 2020
Update on COVID-19 Antibodies

We are pleased to let you know that we now have the first four anti-nucleoprotein antibodies available in their final forms.

Read more
03 Dec, 2020
New Podcasts related to BNP and NT-proBNP

Clinical Chemistry podcasts are highlighting selected articles in the journal. Now our scientists have been guests in the Clinical Chemistry podcasts related to their publications in the same journal.
Listen below the podcasts and learn more about our cardiac markers.

Read more
19 Nov, 2020
Meet us at AACC 2020 – Free Expo Passes Available

AACC’s Annual Scientific Meeting & Clinical Lab Expo, taking place December 14–17, will include many activities that you are used to experiencing in a live event: scientific sessions, poster presentations, an Expo showcase and networking opportunities.
If you or a representative of your company is planning to attend, we would welcome the opportunity to meet with you at our virtual booth.

Read more
23 Oct, 2020
Now Available! COVID-19 Related Monoclonal Antibodies

Our first COVID-19 related monoclonal antibodies are now available

Read more
01 Oct, 2020
Soon Available! COVID-19 Antibodies

Our first COVID-19 related monoclonal antibodies will be soon available: Ten antibodies specific to SARS-CoV-2 nucleoprotein and two antibodies specific to Spike (RBD) will be launched in 2-3 weeks.

Read more
01 Oct, 2020
Editorial: Relevance of an in-Depth Analysis of Molecular Heterogeneity of Circulating NT-proBNP

In the latest Clinical Chemistry editorial our scientist addresses an article about molecular heterogeneity of NT-proBNP/proBNP published in the same issue. In the editorial our scientist discusses the complexity of this circulating heart failure marker, current NT-proBNP assays and how ongoing research including the addressed article could affect the design of future NT-proBNP assays.

Read more
17 Sep, 2020
COVID-19 Antibodies – R&D Samples Available

We are pleased to let you know that we are developing several monoclonal antibodies specific to SARS-CoV2 nucleoproteins (Cat.# 3CV4) and to Spike RBD (Cat.# 3CV2).

Read more
17 Sep, 2020
HyTest Live Webinar - Diagnostics of COVID-19: Achievements, Challenges and Perspectives

By watching this webinar, you will learn about:
- transmission and clinical characteristics of SARS-CoV-2
- the existing testing methods for SARS-CoV-2, including nucleic acid testing, genome sequencing, serological testing for SARS-CoV-2 specific antibodies and antigen testing
- the principles, advantages and limitations of these testing methods
- safety precautions for handling different types of clinical specimens for SARS-CoV-2 detection

Read more
26 Aug, 2020
New Product! SARS-CoV-2 Nucleoprotein

HyTest’s SARS-CoV-2 Nucleoprotein (Cat.# 8COV3) is a full-length recombinant antigen that can be used in serology assays for the detection of COVID-19 specific antibodies.

Read more
26 Aug, 2020
New Product! ST2 Antibodies and Antigen

Soluble ST2 (sST2) biomarker is used for additive risk stratification and prognosis of patients with heart failure (HF). ST2 interacts with IL-33, and IL-33/ST2 system is upregulated in cardiomyocytes and fibroblasts in response to cardiac injury or cardiac stress.

Read more
11 Jul, 2020
New Product! SARS-CoV-2 Spike RBD Antigen

HyTest’s recombinant SARS-CoV-2 Spike RBD is now available. The antigen can be used in the development of COVID-19 serology (antibody) tests.

Read more
02 Jul, 2020
SARS-Cov-2 Nucleoprotein – R&D Samples Available

We are finalizing the development of SARS-CoV-2 Nucleoprotein. The antigen can be used in serology assays.

Read more
25 Jun, 2020
New Product: Recombinant GFAP

We have now developed a recombinant GFAP protein that can be used as a standard or calibrator in GFAP immunoassay development

Read more
24 Jun, 2020
New Article: CT-IGFBP-4 as a Novel Prognostic Biomarker in Acute Heart Failure

Insulin-like growth factor binding protein-4 (IGFBP-4) fragments have been shown to predict the risk of major adverse cardiovascular events, including segment-elevation myocardial infarction, in patients with acute coronary syndrome.

Read more
02 Jun, 2020
SARS-Cov-2 Recombinant Antigen – R&D Samples Available

We are finalizing the development of SARS-Cov-2 Spike RBD recombinant antigen.

Read more
27 May, 2020
New! Polyclonal Antibodies Specific to Canine CRP

In dogs, C-reactive protein (CRP) can be used as a marker of inflammation. Its concentration in blood increases rapidly in systemic inflammation and decreases quickly during recovery. It has been shown to increase in disorders such as bacterial infections, sepsis and pyometra, as well as in the case of post-surgical infections.

Read more

Do you need samples?

We are happy to make you an offer